M Bayssas, J Gouveia, P Ribaud, M Musset, F de Vassal, J L Pico, L de Luca, J L Misset, D Machover, D Belpomme, L Schwarzenberg, C Jasmin, M Hayat, G Mathé
Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid luekemia (55%), and some responses were recorded in lymphosarcoma (40%)...
1979: Cancer Chemotherapy and Pharmacology